The gefitinib dose reduction on survival outcomes in epidermal growth factor receptor mutant non-small cell lung cancer

Tumor Burden is Predictive of Survival in Patients With Non–Small-Cell Lung Cancer and With Activating Epidermal Growth Factor Receptor Mutations Who Receive Gefitinib

(2013) Jin Hyun Park et al.   Clinical Lung Cancer

Rare and complex mutations of epidermal growth factor receptor, and efficacy of tyrosine kinase inhibitor in patients with non-small cell lung cancer

(2013) Bhumsuk Keam et al.   International Journal of Clinical Oncology

Skin Rash could Predict the Response to EGFR Tyrosine Kinase Inhibitor and the Prognosis for Patients with Non-Small Cell Lung Cancer: A Systematic Review and Meta-Analysis

(2013) Hong-bing Liu et al.   PLoS One

Reduced CYP2D6 function is associated with gefitinib-induced rash in patients with non-small cell lung cancer

(2012) Tomohiro Suzumura et al.   BMC CANCER

First-SIGNAL: First-Line Single-Agent Iressa Versus Gemcitabine and Cisplatin Trial in Never-Smokers With Adenocarcinoma of the Lung

(2012) Ji-Youn Han et al.   JOURNAL OF CLINICAL ONCOLOGY

Low-Dose Gefitinib Treatment for Patients with Advanced Non-small Cell Lung Cancer Harboring Sensitive Epidermal Growth Factor Receptor Mutations

(2011) Hironori Satoh et al.   Journal of Thoracic Oncology

Evolutionary Modeling of Combination Treatment Strategies To Overcome Resistance to Tyrosine Kinase Inhibitors in Non-Small Cell Lung Cancer

(2011) Shannon M. Mumenthaler et al.   MOLECULAR PHARMACEUTICS

Clinical impact of dose reductions and interruptions of second-generation tyrosine kinase inhibitors in patients with chronic myeloid leukaemia

(2010) Fabio P. S. Santos et al.   BRITISH JOURNAL OF HAEMATOLOGY

Relative dose intensity of chemotherapy and its impact on outcomes in patients with early breast cancer or aggressive lymphoma

(2010) Hans Wildiers et al.   CRITICAL REVIEWS IN ONCOLOGY HEMATOLOGY

Potent, transient inhibition of BCR-ABL with dasatinib 100 mg daily achieves rapid and durable cytogenetic responses and high transformation-free survival rates in chronic phase chronic myeloid leukemia patients with resistance, suboptimal response or intolerance to imatinib

(2010) N. P. Shah et al.   HAEMATOLOGICA

Association of Polymorphisms in AKT1 and EGFR with Clinical Outcome and Toxicity in Non-Small Cell Lung Cancer Patients Treated with Gefitinib

(2010) E. Giovannetti et al.   MOLECULAR CANCER THERAPEUTICS

Gefitinib or Chemotherapy for Non–Small-Cell Lung Cancer with Mutated EGFR

(2010) Makoto Maemondo et al.   NEW ENGLAND JOURNAL OF MEDICINE

Gefitinib versus cisplatin plus docetaxel in patients with non-small-cell lung cancer harbouring mutations of the epidermal growth factor receptor (WJTOG3405): an open label, randomised phase 3 trial

(2009) Tetsuya Mitsudomi et al.   LANCET ONCOLOGY

Evolution of Resistance to Targeted Anti-Cancer Therapies during Continuous and Pulsed Administration Strategies

(2009) Jasmine Foo et al.   PLoS Computational Biology

Molecular changes of epidermal growth factor receptor (EGFR) and KRAS and their impact on the clinical outcomes in surgically resected adenocarcinoma of the lung

(2007) Young Tae Kim et al.   LUNG CANCER